Caleb anti-cancer drug enters first phase of clinical tests

A new drug developed by Caleb BioMedical Technology for the treatment of gastrointestinal cancer has entered the first phase of clinical tests.

Traditional chemotherapy and target drugs are mainly aimed at specific cells, especially those in rapid proliferation. It means that tumor cells will be greatly affected by chemotherapy drugs, but that some normal cells will also be damaged to varying degrees. This can cause significant side effects in patients.

John M Luk, founder of Caleb, however, has found a target of cancer cells, CDH17, which is highly expressed in the gastrointestinal cancer genome. Caleb, based on Guangzhou International Bio Island, has thus developed a biospecific antibody immunotherapy drug which can instruct the immune system to attack cancer cells, targeting CDH17 precisely, with minimal side effects.

Caleb BioMedical Technology is located in Guangzhou's Huangpu district.

The drug has already passed the certification of Good Manufacturing Practice and obtained patents in the United States, Australia and Israel. Caleb is now cooperating with Chinese, US, Australian, South Korean and Israeli hospitals in clinical tests on different races. It is expected to file biological license applications to the National Medical Products Administration and the US Food and Drug Administration in 2023 after it has collected enough clinical data.

Share - WeChat